Clinical Trials in Atlanta

Showing 17521-17540 of 19,805 trials

Laboratory Study in Predicting Tumor Response to Chemotherapy in Patients With Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00897039

RATIONALE: Collecting samples of tissue from patients with cancer to study in the laboratory may help doctors predict how well patients will respond to treatment with certain chemotherapy drugs and plan the best treatment. PURPOSE: This laboratory study is looking at tumor tissue samples to predict response to chemotherapy in patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer

Southeastern Gynecologic Oncology60 participantsStarted Mar 2006

Atlanta, Georgia, United States

UNKNOWNNA< 1 mile

Internet-Based Nutrition Education Program in Preventing Cancer in Participants of Health Maintenance Organizations

NCT00169312

RATIONALE: Websites for nutrition education may be an effective method to help people eat more fruits and vegetables which may lower their risk of cancer. PURPOSE: This randomized trial is studying how well an internet-based nutrition education program works in preventing cancer in participants of health maintenance organizations.

Unspecified Adult Solid Tumor, Protocol Specific

Josephine Ford Cancer Center2,619 participantsStarted Aug 2005

Denver, Colorado, United States • Atlanta, Georgia, United States • Minneapolis, Minnesota, United States +1 more locations

COMPLETEDPhase 2< 1 mile

Treatment Interruption of Natalizumab

NCT01071083

This is a randomized, rater blinded trial in patients who interrupt treatment with natalizumab with or without being treated with other immunomodulatory drugs, or continue treatment with natalizumab. The main purpose of this study is to find out the following, when participants stop taking natalizumab for 24 weeks: * when MS symptoms return, and * if other drugs for MS may help control MS symptoms during the natalizumab-interruption period. This study will also explore how quickly the effects of natalizumab return after resuming natalizumab dosing.

Relapsing Remitting Multiple Sclerosis

Biogen175 participantsStarted Mar 2010

Cullman, Alabama, United States • San Francisco, California, United States • Fort Collins, Colorado, United States +30 more locations

Laboratory Study in Predicting Tumor Response to Chemotherapy in Patients With Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Internet-Based Nutrition Education Program in Preventing Cancer in Participants of Health Maintenance Organizations

Treatment Interruption of Natalizumab

Find Trials by Condition in Atlanta

Surgical Treatment for Acute Patella Tendon Rupture

Efficacy and Safety Study of Norethindrone Acetate Transdermal Delivery System in Contraception

Exercise Program or Health Education Program in Reducing Fatigue and Pain in Breast Cancer Survivors

TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in Schizophrenia

OVATIO CRT and SITUS OTW LV Lead Post Approval Study

Nutrition Intervention in Treating Women With Breast Cancer

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus

A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer

Kineflex Artificial Disc System to Treat Degenerative Disc Disease (DDD)

A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes

Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)

Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors

A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Measure Response to Etanercept in Rheumatoid Arthritis